{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T22:05:59Z","timestamp":1768601159683,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.humpath.2025.106005","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:16:59Z","timestamp":1764951419000},"page":"106005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Correlation of lymphocytic infiltration and degree of pleomorphism with tumor mutation burden in high-grade urothelial carcinoma"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-1787","authenticated-orcid":false,"given":"Neslihan","family":"Kayraklioglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Kuang","family":"Cornelia Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy Y.","family":"Greenland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley A.","family":"Stohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffry P.","family":"Simko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0848-4172","authenticated-orcid":false,"given":"Deepika","family":"Sirohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2025.106005_bib1","series-title":"Urinary and male genital tumours","year":"2022"},{"key":"10.1016\/j.humpath.2025.106005_bib2","series-title":"Bladder cancer","year":"12025"},{"key":"10.1016\/j.humpath.2025.106005_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.humpath.2020.07.006","article-title":"Invasive plasmacytoid urothelial carcinoma: a comparative study of E-cadherin and P120 catenin","volume":"102","author":"Sangoi","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2025.106005_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","article-title":"Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype","volume":"80","author":"Zinnall","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2025.106005_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2024.04.012","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases","volume":"148","author":"Zheng","year":"2024","journal-title":"Hum Pathol"},{"issue":"12","key":"10.1016\/j.humpath.2025.106005_bib6","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The world health organization\/international society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2025.106005_bib7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.eururo.2024.08.013","article-title":"The importance of being grade 3: a plea for a three-tier hybrid classification system for grade in primary non-muscle-invasive bladder cancer","volume":"86","author":"Beijert","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.humpath.2025.106005_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.pathol.2021.10.005","article-title":"The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes","volume":"54","author":"Downes","year":"2022","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.humpath.2025.106005_bib9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/his.15438","article-title":"Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international uropathology study","volume":"87","author":"Downes","year":"2025","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.humpath.2025.106005_bib10","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.humpath.2025.106005_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.humpath.2025.106005_bib12","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.humpath.2025.106005_bib13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.humpath.2025.106005_bib14","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1002\/jcp.29279","article-title":"Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma","volume":"235","author":"Zhang","year":"2020","journal-title":"J Cell Physiol"},{"issue":"19","key":"10.1016\/j.humpath.2025.106005_bib15","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","article-title":"Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended Follow-up from CheckMate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10122","key":"10.1016\/j.humpath.2025.106005_bib16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.humpath.2025.106005_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102198","article-title":"Association of tumor mutational burden and microsatellite instability with response and outcomes in patients with urothelial carcinoma treated with immune checkpoint inhibitor","volume":"22","author":"Bakaloudi","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.humpath.2025.106005_bib18","article-title":"Tumor mutational burden as a predictor of first-line immune checkpoint inhibitor versus carboplatin benefit in cisplatin-unfit patients with urothelial carcinoma","volume":"6","author":"Graf","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.humpath.2025.106005_bib19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive analysis of hypermutation in human cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"issue":"7463","key":"10.1016\/j.humpath.2025.106005_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.humpath.2025.106005_bib21","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.18632\/oncotarget.23344","article-title":"APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response","volume":"9","author":"Glaser","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2025.106005_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.816706","article-title":"APOBEC mutational signature and tumor mutational burden as predictors of clinical outcomes and treatment response in patients with advanced urothelial cancer","volume":"12","author":"Natesan","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.humpath.2025.106005_bib23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","article-title":"MSIsensor: microsatellite instability detection using paired tumor-normal sequence data","volume":"30","author":"Niu","year":"2014","journal-title":"Bioinformatics"},{"issue":"8","key":"10.1016\/j.humpath.2025.106005_bib24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jmoldx.2024.05.002","article-title":"Recommendations for tumor mutational burden assay validation and reporting: a joint consensus recommendation of the association for molecular pathology, college of American pathologists, and society for immunotherapy of cancer","volume":"26","author":"Furtado","year":"2024","journal-title":"J Mol Diagn"},{"issue":"7","key":"10.1016\/j.humpath.2025.106005_bib25","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jtho.2020.01.023","article-title":"Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study","volume":"15","author":"Stenzinger","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2025.106005_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the friends of cancer research TMB harmonization project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.humpath.2025.106005_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/PAS.0000000000002165","article-title":"Specific pathology features enrich selection of endometrial carcinomas for POLE testing","volume":"48","author":"Keyhanian","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2025.106005_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.633243","article-title":"Clinicopathological features, tumor mutational burden, and tumour-infiltrating lymphocyte interplay in ERBB2-Mutated breast cancer: in silico analysis","volume":"27","author":"Uchida","year":"2021","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"10.1016\/j.humpath.2025.106005_bib29","first-page":"44","article-title":"The prognostic value of tumor mutation burden and immune cell infiltration in thymic epithelial tumors","volume":"51","author":"Du","year":"2021","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.humpath.2025.106005_bib30","article-title":"Tumor-infiltrating lymphocytes, tumor mutational burden, and genetic alterations in microsatellite unstable, microsatellite stable, or mutant POLE\/POLD1 Colon cancer","volume":"5","author":"Keshinro","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.humpath.2025.106005_bib31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/oncolo\/oyae054","article-title":"Automated quantitative CD8+ tumor-infiltrating lymphocytes and tumor mutation burden as independent biomarkers in melanoma patients receiving front-line Anti-PD-1 immunotherapy","volume":"29","author":"Fortman","year":"2024","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.humpath.2025.106005_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041210","article-title":"Association between tumor mutational burden, stromal CD8(+) tumor-infiltrating lymphocytes, and clinical factors in cervical cancers treated with radiotherapy","volume":"15","author":"Ruan","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.humpath.2025.106005_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary Ta\/T1 non-muscle-invasive bladder cancer: a multicenter European Association of urology non-Muscle-invasive bladder cancer guidelines panel study","volume":"4","author":"van Rhijn","year":"2021","journal-title":"Eur Urol Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725002928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725002928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:32:16Z","timestamp":1768555936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725002928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"alternative-id":["S0046817725002928"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.106005","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation of lymphocytic infiltration and degree of pleomorphism with tumor mutation burden in high-grade urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.106005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106005"}}